Yahoo HomeAston Martin DBX's blue interior
Editor-in-Chief Greg Migliore showcases the all-new Aston Martin DBX interior.
Make Yahoo Your Homepage
Discover something new every day from News, Sports, Finance, Entertainment and more!
Editor-in-Chief Greg Migliore showcases the all-new Aston Martin DBX interior.
Mike Lindell has a very unusual definition of "free speech."
During the three-game sweep, the Detroit Tigers collected 20 runs on 31 hits and 13 walks against the Houston Astros.
NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against SOS Limited (“SOS” or the “Company”) (NYSE: SOS), and certain of its officers. The class action, filed in the United States (“U.S.”) District Court for the District of New Jersey, and docketed under 21-cv-07454, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired SOS American depository shares (“ADSs”) between July 22, 2020 and February 25, 2021, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission (“SEC”), against the Company and certain of its top officials. If you are a shareholder who purchased SOS ADSs during the Class Period, you have until May 31, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] SOS is a technology company that purportedly provides marketing data, technology, and solutions for emergency rescue services. When the Company went public in April 2017, it was known as “China Rapid Finance Limited” and claimed to focus on a peer-to-peer, micro-lending business. The Company later changed its name to “SOS Limited” in July 2020 and sold its peer-to-peer, micro-lending business in August 2020, rebranding itself into an emergency services business. In January 2021, the Company again shifted its business focus, this time to cryptocurrency mining. Critical to SOS’s purportedly successful transition into a cryptocurrency mining business were the Company’s claims to have entered into an agreement with HY International Group New York Inc. (“HY”), which calls itself the “world’s largest mining machine matchmaker,” to acquire 15,645 mining rigs—i.e., personal computing machines built specifically for cryptocurrency mining—for $20 million, and the Company’s plans to purchase FXK Technology Corporation (“FXK”), a purported Canadian cryptocurrency technology firm. In addition to rapidly changing its business focus, SOS has also rapidly changed the location of its headquarters. According to the Company’s SEC filings, the address of the Company’s principal executive offices has changed no less than five times since the Company went public in April 2017. The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) SOS had misrepresented the true nature, location, and/or existence of at least one of the principal executive offices listed in its SEC filings; (ii) HY and FXK were either undisclosed related parties and/or entities fabricated by the Company; (iii) the Company had misrepresented the type and/or existence of the mining rigs that it claimed to have purchased; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times. On February 26, 2021, Hindenburg Research (“Hindenburg”) and Culper Research (“Culper”) released commentary on SOS, claiming that the Company was an intricate “pump and dump” scheme that used fake addresses and doctored photos of crypto mining rigs to create an illusion of success. The analysts noted, for example, that SOS’s SEC filings listed a hotel room as the Company’s headquarters. The analysts also questioned whether SOS had actually purchased mining rigs that it claimed to own, as the entity from which SOS purportedly bought the mining rigs appeared to be a fake shell company. The analysts further alleged that the photos SOS had published of their purported “mining rigs” were phony. Culper noted that photographs of SOS’s “miners” did not depict the A10 Pro machines that the Company claimed to own and instead appeared to show different devices altogether. Hindenburg, for its part, found that the original images from SOS’s website actually belonged to another company. On this news, SOS’s American depositary share (“ADS”) price fell $1.27 per share, or 21.03%, to close at $4.77 per ADS on February 26, 2021. After the end of the Class Period, between February 27 and March 3, 2021, Hindenburg subsequently provided additional information on SOS that further supported its earlier allegations, including pictures, highlighting, inter alia, how SOS had allegedly taken steps to hide the misconduct noted in the February 26, 2021 corrective disclosures. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com 888-476-6529 ext. 7980
NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Plug Power Inc. (“Plug Power” or the “Company”) (NASDAQ: PLUG) and certain of its officers. The class action, filed in the United States District Court for the Central District of California, and docketed under 21-cv-02402, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Plug securities between November 9, 2020 and March 1, 2021, inclusive (the “Class Period”). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the “Exchange Act”). If you are a shareholder who purchased Plug Power securities during the Class Period, you have until May 7, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Plug provides comprehensive hydrogen fuel cell turnkey solutions focused on systems used to power electric motors in the electric mobility and stationary power markets. The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company would be unable to timely file its 2020 annual report due to delays related to the review of classification of certain costs and the recoverability of the right to use assets with certain leases; (2) that the Company was reasonably likely to report material weaknesses in its internal control over financial reporting; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On March 2, 2021, before the market opened, Plug filed a Notification of Late Filing with the SEC stating that it could not timely file its annual report for the period ended December 31, 2020 because the Company was completing a “review and assessment of the treatment of certain costs with regards to classification between Research and Development versus Costs of Goods Sold, the recoverability of right of use assets associated with certain leases, and certain internal controls over these and other areas.” The Company stated that “[i]t is possible that one or more of these items may result in charges or adjustments to current and/or prior period financial statements.” On this news, the Company’s stock price fell $3.68, or 7%, to close at $48.78 per share on March 7, 2021, on unusually heavy trading volume. The share price continued to decline by $9.48, or 19.4%, over three consecutive trading sessions to close at $39.30 per share on March 5, 2021, on unusually heavy trading volume. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com888-476-6529 ext. 7980
Detroit Tigers game time, TV channel (Bally Sports Detroit), radio info (97.1 FM), score, live updates and analysis as they play the Houston Astros.
Joel Greenberg made more than 150 payments to dozens of women, including a minor, The Daily Beast reported.
Officers sprayed a crowd from behind a fence surrounding the Brooklyn Center police department, on April 14, video shows, as protesters shielded using umbrellas.Demonstrations over the shooting of Daunte Wright began for a fourth consecutive night on Wednesday. Public safety officials issued multiple dispersal warnings before a curfew began and warned protesters who did not leave the area would be arrested.In video shared on Twitter by Brendan Gutenschwager, officers can be seen spraying protesters from behind a fence at the Brooklyn Center police station while the protesters shield behind umbrellas. One protester can also be seen approaching the fence surrounding the station and attempts to speak with the officers.Demonstrations began in Brooklyn Center after a police officer fatally shot Daunte Wright during a traffic stop on April 11. The officer involved in the shooting, Kim Potter, was charged with second-degree manslaughter on April 14, according to media reports. Credit: Brendan Gutenschwager via Storyful
Protesters gathered in a neighborhood in Columbia, South Carolina, on April 14 to demonstrate against a soldier who earlier pushed and threatened a black man in the area.Fort Jackson soldier Jonathan Pentland was charged over the incident, according to the Fort Jackson Commanding General.“The leaders at Fort Jackson in no way condone the behavior depicted in the video posted recently,” the Fort Jackson Commanding General wrote in a Facebook post.“You’re in the wrong neighborhood m********”, the soldier says in the video that went viral on Twitter. Credit: Alexis Sincere via Storyful
The former officer who shot Daunte Wright in Minneapolis faces a charge of second-degree manslaughter.
Chinese fans breathed a sigh of relief Wednesday after Warner Bros. at last announced finalized China re-release dates for the first two “Lord of the Rings” films — a scant two days before the first is now scheduled to appear. Official Chinese film media had initially stated in late March that re-runs of “The Fellowship […]
Reggie Jackson's game winning shot with 2.3 seconds left pushes the Los Angeles Clippers past the Detroit Pistons, 100-98, on Wednesday.
When Thailand's transport minister was recently diagnosed with COVID-19, it was Prime Minister Prayuth Chan-ocha who got a headache. Prayuth was not particularly lauded for his leadership last year against the coronavirus, but for much of 2020 Thailand fought the disease to a standstill, with low infection and death rates envied by more developed countries. Now, an outbreak at nightspots in the capital Bangkok has sent new infections surging, suggesting the country may have been lulled into a false sense of security before mass vaccinations begin.
The content delivery network (CDN) market is expected to grow by USD 48.48 billion during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the content delivery network (CDN) market in optimistic, probable, and pessimistic forecast scenarios.
Carlos Rodón threw the majors' second no-hitter of the season Wednesday night, losing his bid for a perfect game on a hit batter in the ninth inning, and the Chicago White Sox cruised to an 8-0 victory over the Cleveland Indians. Working quickly in short sleeves with the top of his jersey unbuttoned on a cool Chicago night, Rodón threw 75 of his 114 pitches for strikes. The No. 3 pick in the 2014 amateur draft out of North Carolina State struck out seven in his first career shutout and second complete game.
Rodón nearly had a perfect game against the Cleveland Indians, but hit a batter on the toe in the ninth inning. He still managed to complete the no-hitter.
(Bloomberg) -- Oil was steady in Asia after jumping almost 5% on Wednesday as U.S. stockpiles data added to signs the demand outlook is improving.Futures in New York traded near $63 a barrel after closing higher for a third day, the longest run of gains in more than a month. U.S. crude inventories dropped the most in almost two months last week, while a gauge of gasoline demand ticked higher for a seventh straight week. The bullish data followed upbeat assessments by OPEC and the International Energy Agency.Oil had been stuck near $60 a barrel after a rally faltered in mid-March amid a resurgence in virus cases in some regions. While the IEA sees a temporary lull in the market due to the renewed outbreaks, it followed OPEC in boosting its demand estimates for this year as the economy rebounds from the pandemic.The market will soon have to deal with more supply, however. OPEC+ and U.S. producers are set to start adding extra barrels from May. Another wildcard is Iran, which is seeking to revive a 2015 nuclear deal and have U.S. sanctions removed to lift crude exports, but progress on that remains uncertain.“Consolidation is likely on the cards as crude may have overshot yesterday,” said Vandana Hari, founder of Vanda Insights in Singapore. “The spike appears to reflect a selective view of a multi-speed world. Europe is still in the throes of Covid’s constraints and India is plunging into a deadlier second wave.”The prompt timespread for Brent was 43 cents a barrel in backwardation -- where near-dated contracts are more expensive than later-dated ones. That compares with 49 cents a week earlier.See also: Oil Agencies Bet on Vaccine Win for Second-Half Demand OptimismU.S. crude stockpiles declined by 5.89 million barrels last week, according to Energy Information Administration data. Gasoline inventories increased for a second week, while distillate supplies -- a category that includes diesel -- dropped for the first time since early March.The global recovery from the pandemic is looking uneven, however. The U.S. and China are seeing higher rates of fuel consumption, but India is renewing partial lockdowns amid record virus cases and a shortage of vaccines. South Korea and Japan are also seeing rising infections.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) and certain of its officers. The class action, filed in the United States District Court for the Western District of New York, and docketed under 21-cv-00413, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquire Athenex common stock between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). This action is brought on behalf of the Class for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), 15 U.S.C. §§ 78j(b) and 78t(a) and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission, 17 C.F.R. § 240.10b-5. If you are a shareholder who purchased Athenex securities during the Class Period, you have until May 3, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Athenex is a “global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer.” Athenex is “organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform.” One of the Company’s main drug candidates is an oral paclitaxel and encequidar for the treatment of metastatic breast cancer. On August 7, 2019, Athenex announced topline data showing that oral paclitaxel and encequidar met the primary efficacy endpoint with statistically significant improvement over IV paclitaxel in a Phase 3 pivotal study in metastatic breast cancer. In this release, the Company stated that it intended to seek a pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) and would “be preparing our NDA submission as soon as possible.” Over the next several months, Defendants continued to laud their Phase 3 study of oral paclitaxel plus encequidar. On September 1, 2020, the Company announced that the FDA had accepted for filing Athenex’s NDA for Oral Paclitaxel and Encequidar in metastatic breast cancer with priority review. In this release, Athenex announced that the FDA had set a target action date of February 28, 2021 for the Company’s NDA, and that “the FDA has communicated that it is not currently planning to hold an advisory committee meeting to discuss the application.” Then, on December 9, 2020, Athenex announced that it had presented updated Phase 3 data on survival and tolerability associated with Oral Paclitaxel and Encequidar in patients with metastatic breast cancer. The Company announced that it had presented this Phase 3 data at the 2020 San Antonio Breast Cancer Symposium, and that the data “demonstrat[ed] clinical benefits in efficacy and tolerability of oral paclitaxel versus IVP in patents with metastatic breast cancer . . . . The findings further support the superiority of increased ORR [objective response rate] observed with oral paclitaxel.” The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) that the Company’s Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommend a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company’s NDA in its current form; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times. Before the markets opened on March 1, 2021, Athenex issued a press release entitled “Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer.” In this release, Athenex noted that the “FDA Issues a CRL to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form.” This release further provided that “[i]n the CRL, the FDA indicated its concern of safety risk to patients in terms of an increase in neutropenia-related sequalae on the Oral Paclitaxel arm compared with the IV paclitaxel arm.” In this March 1, 2021 press release, Athenex further stated that the “FDA also expressed concerns regarding the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by blinded independent centra review (BICR). The [FDA] stated that the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR.” Last, in this release, Athenex wrote that the FDA “recommended that Athenex conduct a new adequate and well-conducted clinical trial in a patient population with metastatic breast cancer representative of the population of the U.S. The [FDA] determined that additional risk mitigation strategies to improve toxicity, which may involve dose optimization and / or exclusion of patients deemed to be at a higher risk of toxicity, are required to support potential approval of the NDA.” On this news, the price of Athenex’s shares plummeted from their February 26, 2021 closing price of $12.10 per share to a March 1, 2021 close of just $5.46 each. This represents a one-day drop of approximately 55%, representing hundreds of millions of dollars in lost market capitalization. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com888-476-6529 ext. 7980
The 30-year-old entertainer has teamed up with Unlisted Brand Lab for the new venture. Though details are limited, the line is expected to launch in the fall.
Just five days after Joe Musgrove threw the first no-hitter of the 2021 season, Chicago White Sox pitcher Carlos Rodon threw the second vs. Cleveland.
(Bloomberg) -- Most Asian equities dipped Thursday after U.S. indexes eased from all-time peaks, with the drop in cryptocurrency exchange Coinbase Global Inc. overshadowing strong bank earnings. Oil trimmed earlier gains.Shares fell in Hong Kong and China as the central bank effectively drained cash from the financial system, adding to concerns about tightening liquidity. Tech stocks also struggled. Japan and South Korea edged higher. U.S. futures fluctuated after Coinbase traded down in its Nasdaq debut. Bank stocks gained overnight on revenue windfalls for the likes of Goldman Sachs Group Inc.The dollar inched upward after three straight days of losses, and the benchmark 10-year Treasury yield held around 1.63%.In Asia’s session, investors are also watching for further tremors from the sharp selloff in the bonds of distressed-debt enterprise China Huarong Asset Management Co., which has pushed investment-grade spreads higher.With equities hovering around record levels, traders are watching the earnings season for further catalysts. Expectations for a strong profit rebound have buoyed indexes, setting the bar high as reporting gets underway. More broadly, investors are alert to any setbacks to the economic recovery from spikes in Covid-19 infections and troubled vaccine rollouts.“You’re going to see this tug-of-war continue within markets as investors weigh the prospects of a strengthening economy with the risk of rising inflationary pressures,” said Adam Phillips, managing director of portfolio strategy at EP Wealth Advisors.The Federal Reserve remains committed to supporting the recovery, and will start tapering asset purchases “well before” policy makers consider raising interest rates, Chairman Jerome Powell told the Economic Club of Washington Wednesday.Bitcoin touched a record of $64,870 before slipping. Oil trimmed an overnight surge but remained around $63 a barrel as shrinking crude stockpiles in the U.S. supported hopes for a global demand recovery.Some key events to watch this week:U.S. data including initial jobless claims, industrial production and retail sales come Thursday.China economic growth, industrial production and retail sales figures are on Friday.These are some of the main moves in financial markets:StocksS&P 500 futures edged up 0.1% as of noon in Tokyo. The index closed down 0.4%.Japan’s Topix Index was up 0.4%.The Shanghai Composite slipped 1.1%.The Hang Seng was down 1.1%.South Korea’s Kospi Index rose 0.2%.Australia’s S&P/ASX 200 Index added 0.1%.CurrenciesThe Bloomberg Dollar Spot Index rose less than 0.1%.The euro was at $1.1974.The Japanese yen was little changed at 108.92 per dollar.The offshore yuan was at 6.5410 per dollar, down 0.1%.BondsThe yield on 10-year Treasuries was at 1.63%.Australia’s 10-year yield was up three basis points to 1.78%.CommoditiesWest Texas Intermediate crude slipped 0.1% to $63.07 a barrel.Gold added 0.2% to $1,739 an ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.